[Long-term treatment of senile macular degeneration with Cosaldon A+E].
During the early phase of senile degeneration of the macula treatment with Cosaldon A+E offers real changes of improvement. In the later phases long-term Cosaldon therapy can bring about an appreciable improvement when other vasoactive substances are administered at intervals. The addition of the vitamins A and E improves the efficacy of Cosaldon. Results in 157 patients are supported by statistics.
D000328:Adult; D000368:Aged; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D013805:Theobromine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014792:Visual Acuity / Q000187:drug effects; D014801:Vitamin A / Q000627:therapeutic use*; D014810:Vitamin E / Q000627:therapeutic use*
D004338:Drug Combinations; D009539:Nicotinic Acids; C007138:nicotinic acid, pentifylline drug combination; D014801:Vitamin A; D014810:Vitamin E; C025790:vitamin A, pentifyllin, nicotinic acid, and vitamin E combination; D013805:Theobromine
Langzeitbehandlung der senilen Makuladegeneration mit Cosaldon A+E.